SYRE vs. FXAIX

Last updated Apr 1, 2026

Compare and contrast key facts about Spyre Therapeutics Inc. (SYRE) and Fidelity 500 Index Fund (FXAIX).

FXAIX is a passively managed fund by Fidelity that tracks the performance of the S&P 500 Index. It was launched on Feb 17, 1988.

Performance

SYRE vs. FXAIX - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Spyre Therapeutics Inc. (SYRE) and Fidelity 500 Index Fund (FXAIX). The values are adjusted to include any dividend payments, if applicable.

SYRE vs. FXAIX - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020	2019	2018	2017
SYRE Spyre Therapeutics Inc.	53.97%	40.72%	8.18%	91.33%	-90.53%	-39.64%	3.01%	2.00%	38.45%	24.37%
FXAIX Fidelity 500 Index Fund	-4.34%	17.84%	25.01%	26.29%	-18.14%	28.71%	18.42%	31.48%	-4.43%	21.82%

Returns By Period

In the year-to-date period, SYRE achieves a 53.97% return, which is significantly higher than FXAIX's -4.34% return.

SYRE

• 1D: 11.05%
• 1M: 17.28%
• YTD: 53.97%
• 6M: 200.95%
• 1Y: 212.61%
• 3Y*: 90.90%
• 5Y*: -24.14%
• 10Y*: —

FXAIX

• 1D: 2.92%
• 1M: -5.02%
• YTD: -4.34%
• 6M: -2.14%
• 1Y: 17.32%
• 3Y*: 18.30%
• 5Y*: 11.79%
• 10Y*: 14.08%

*Multi-year figures are annualized to reflect compound growth (CAGR)

Return for Risk

SYRE vs. FXAIX — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

SYRE

SYRE Risk / Return Rank: 95
SYRE Sharpe Ratio Rank: 97
SYRE Sortino Ratio Rank: 94
SYRE Omega Ratio Rank: 91
SYRE Calmar Ratio Rank: 96
SYRE Martin Ratio Rank: 96

FXAIX

FXAIX Risk / Return Rank: 60
FXAIX Sharpe Ratio Rank: 48
FXAIX Sortino Ratio Rank: 53
FXAIX Omega Ratio Rank: 56
FXAIX Calmar Ratio Rank: 64
FXAIX Martin Ratio Rank: 76

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

SYRE vs. FXAIX - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Spyre Therapeutics Inc. (SYRE) and Fidelity 500 Index Fund (FXAIX). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	SYRE	FXAIX	Difference
Sharpe ratio Return per unit of total volatility	3.11	0.97	+2.13
Sortino ratio Return per unit of downside risk	3.40	1.49	+1.91
Omega ratio Gain probability vs. loss probability	1.41	1.23	+0.19
Calmar ratio Return relative to maximum drawdown	6.74	1.52	+5.22
Martin ratio Return relative to average drawdown	17.68	7.30	+10.38
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

SYRE vs. FXAIX - Sharpe Ratio Comparison

The current SYRE Sharpe Ratio is 3.11, which is higher than the FXAIX Sharpe Ratio of 0.97. The chart below compares the historical Sharpe Ratios of SYRE and FXAIX, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Sharpe Ratios by Period

	SYRE	FXAIX	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	3.11	0.97	+2.13
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	-0.14	0.70	-0.84
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	—	0.78	—
Sharpe Ratio (All Time) Calculated using the full available price history	-0.11	0.76	-0.87

Correlation

The correlation between SYRE and FXAIX is 0.27, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.

Dividends

SYRE vs. FXAIX - Dividend Comparison

SYRE has not paid dividends to shareholders, while FXAIX's dividend yield for the trailing twelve months is around 1.16%.

	TTM	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
SYRE Spyre Therapeutics Inc.	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
FXAIX Fidelity 500 Index Fund	1.16%	1.11%	1.25%	1.45%	1.69%	1.22%	1.60%	2.06%	2.72%	1.97%	2.52%	2.83%

Drawdowns

SYRE vs. FXAIX - Drawdown Comparison

The maximum SYRE drawdown since its inception was -99.11%, which is greater than FXAIX's maximum drawdown of -33.79%. Use the drawdown chart below to compare losses from any high point for SYRE and FXAIX.

Drawdown Indicators

	SYRE	FXAIX	Difference
Max Drawdown Largest peak-to-trough decline	-99.11%	-33.79%	-65.32%
Max Drawdown (1Y) Largest decline over 1 year	-23.82%	-12.13%	-11.69%
Max Drawdown (5Y) Largest decline over 5 years	-98.74%	-24.50%	-74.24%
Max Drawdown (10Y) Largest decline over 10 years	—	-33.79%	—
Current Drawdown Current decline from peak	-83.17%	-6.23%	-76.94%
Average Drawdown Average peak-to-trough decline	-62.41%	-3.83%	-58.58%
Ulcer Index Depth and duration of drawdowns from previous peaks	10.25%	2.53%	+7.72%

Volatility

SYRE vs. FXAIX - Volatility Comparison

Spyre Therapeutics Inc. (SYRE) has a higher volatility of 19.85% compared to Fidelity 500 Index Fund (FXAIX) at 5.34%. This indicates that SYRE's price experiences larger fluctuations and is considered to be riskier than FXAIX based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	SYRE	FXAIX	Difference
Volatility (1M) Calculated over the trailing 1-month period	19.85%	5.34%	+14.51%
Volatility (6M) Calculated over the trailing 6-month period	47.44%	9.53%	+37.91%
Volatility (1Y) Calculated over the trailing 1-year period	69.73%	18.32%	+51.41%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	178.69%	16.92%	+161.77%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	136.54%	18.05%	+118.49%